We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration, or FDA, on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. CDAD is the most common symptom of Clostridium difficile infection, or CDI. We market DIFICID in the United States through our own sales force and through our co-promotion agreement with Cubist Pharmaceuticals, Inc., or Cubist.
Company profile
Ticker
OPTR
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
330830300
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
26 Mar 15
CT ORDER
Confidential treatment order
20 Feb 14
15-12B
Securities registration termination
4 Nov 13
EFFECT
Notice of effectiveness
29 Oct 13
25-NSE
Exchange delisting
24 Oct 13
8-K
Completion of Acquisition or Disposition of Assets
24 Oct 13
POS AM
Prospectus update (post-effective amendment)
24 Oct 13
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Oct 13
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Oct 13
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Oct 13